Allergan

Supreme Court sends Allergan packing over Restasis tribal licensing strategy
Supreme Court sends Allergan packing over Restasis tribal licensing strategy
Fierce Pharma
Allergan
Supreme Court
Restasis
Flag link:
Influential proxy firms kick back at activists’ demands for Brent Saunders to give up his chairman’s title at Allergan
Influential proxy firms kick back at activists’ demands for Brent Saunders to give up his chairman’s title at Allergan
Endpoints
Allergan
Brent Saunders
activists
Flag link:
Allergan’s failed depression drug shows promise in opioid withdrawal
Allergan’s failed depression drug shows promise in opioid withdrawal
Fierce Biotech
Allergan
rapastinel
Naurex
opioids
opioid withdrawal
Flag link:
Allergan eye drug fails to impress on safety, upping pressure ahead of key meeting
Allergan eye drug fails to impress on safety, upping pressure ahead of key meeting
Biopharma Dive
Allergan
abicipar
wet age-related macular degeneration
Flag link:
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Endpoints
Allergan
abicipar
wet age-related macular degeneration
Lucentis
Molecular Partners
Flag link:
Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed
Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed
Fierce Pharma
Allergan
investors
M&A
Bob Hugin
Flag link:
Allergan's NDA for Migraine Med With Novel Mechanism of Action Accepted by FDA
Allergan's NDA for Migraine Med With Novel Mechanism of Action Accepted by FDA
BioSpace
Allergan
migraines
ubrogepant
FDA
Flag link:
Allergan Rises After FDA Accepts License Applications for Botox Supplements
Allergan Rises After FDA Accepts License Applications for Botox Supplements
TheStreet.com
Allergan
Botox
FDA
pediatrics
limb spascity
Flag link:
Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
Fierce Pharma
Allergan
investors
rapastinel
Flag link:
‘Brutal disaster.’ Allergan’s would-be antidepressant fails patients in four studies
‘Brutal disaster.’ Allergan’s would-be antidepressant fails patients in four studies
Stat
Allergan
antidepressants
repastinel
clinical trials
Flag link:
What do Allergan activists really want? A new CEO to replace Saunders, analyst says
What do Allergan activists really want? A new CEO to replace Saunders, analyst says
Fierce Pharma
Allergan
activists
Pharma CEOs
Brent Saunders
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Sorry, Allergan. Another activist backs an immediate split to CEO, chairman jobs
Sorry, Allergan. Another activist backs an immediate split to CEO, chairman jobs
Fierce Pharma
Allergan
Brent Saunders
Pharma CEOs
Flag link:
Under-pressure Allergan backs a CEO-chairman job split—just not right now
Under-pressure Allergan backs a CEO-chairman job split—just not right now
Fierce Pharma
Allergan
Pharma CEOs
Brent Saunders
Flag link:
Evolus' Botox competitor is here. Will it dent Allergan's sales?
Evolus' Botox competitor is here. Will it dent Allergan's sales?
Fierce Pharma
Allergan
Botox
Evolus
Jeuveau
Flag link:
Even with new competition, Botox can hold its own in growing migraine field: Allergan executives
Even with new competition, Botox can hold its own in growing migraine field: Allergan executives
Fierce Pharma
Allergan
Botox
Amgen
Eli Lilly
Teva Pharmaceuticals
migraines
Flag link:
Allergan sheds $4.5B in market cap on 4Q18 earnings
Allergan sheds $4.5B in market cap on 4Q18 earnings
BioCentury
Allergan
earnings
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy
Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy
Endpoints
Aurinia Pharmaceuticals
voclosporin
eye health
dry eye disease
Allergan
Restasis
Flag link:
Tribe, Allergan appeal sovereign immunity patent case to Supreme Court
Tribe, Allergan appeal sovereign immunity patent case to Supreme Court
BioCentury
Allergan
Supreme Court
inter partes review
Flag link:

Pages